16728-03-3

Basic information

• Product Name: [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL
• Synonyms: [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL
• CAS NO: 16728-03-3
• Molecular Formula: C₁₁H₁₄O₂
• Molecular Weight: 178.22766
• Mol File: 16728-03-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL(16728-03-3)
• EPA Substance Registry System: [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL(16728-03-3)

Safety Data

• Hazardous Substances Data: 16728-03-3(Hazardous Substances Data)

Usage

Description

[1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL, also known as 4-methoxycyclopropylbenzyl alcohol, is a chemical compound characterized by a cyclopropyl ring attached to a phenyl group and a methoxy group. This unique molecular structure endows it with specific reactivity, making it a valuable reagent in the fields of organic synthesis and medicinal chemistry research.

Uses

Used in Pharmaceutical Industry:
[1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique molecular structure and reactivity contribute to the development of new drugs and therapeutic agents.
Used in Drug Discovery and Development:
In the field of drug discovery and development, [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL serves as a key intermediate in the creation of novel chemical entities with potential therapeutic applications. Its versatility in organic synthesis allows for the exploration of new drug candidates with improved efficacy and safety profiles.
Used in Production of Fine Chemicals:
[1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL is also utilized in the production of fine chemicals, which are high-purity chemicals used in various industries, including pharmaceuticals, agriculture, and materials science. Its role in this application is to provide a structural foundation for the synthesis of complex and high-value chemical products.

Upstream product

• 104-47-2 p-methoxybenzylnitrile 
• 16728-00-0 1-(4-methoxyphenyl)cyclopropane-1-carbonitrile 
• 779206-51-8 1-(4-methoxyphenyl)cyclopropanecarboxylic acid methyl ester 
• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 

Downstream Products

• 34603-55-9 1-(4-methoxyphenyl)cyclopropane-1-carbaldehyde 
• 251990-49-5 4-[1-(hydroxymethyl)cyclopropyl]phenol 
• 251996-73-3 4-{1-[[2-(2-ethoxyethoxy)ethoxy]methyl]cyclopropyl}anisole 
• 1026047-57-3 3,5-bis-[4-(1-trityloxymethyl-cyclopropyl)-phenoxy]-pyridine-4-carbaldehyde 
• 1027553-42-9 3,5-bis-(4-{1-[2-(2-ethoxy-ethoxy)-ethoxymethyl]-cyclopropyl}-phenoxy)-pyridine-4-carbaldehyde 

Relevant articles and documents

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl- l -methionine Pocket

A fragment screening approach designed to target specifically the S-adenosyl-l-methionine pocket of catechol O-methyl transferase allowed the identification of structurally related fragments of high ligand efficiency and with activity on the described orthogonal assays. By use of a reliable enzymatic assay together with X-ray crystallography as guidance, a series of fragment modifications revealed an SAR and, after several expansions, potent lead compounds could be obtained. For the first time nonphenolic and small low nanomolar potent, SAM competitive COMT inhibitors are reported. These compounds represent a novel series of potent COMT inhibitors that might be further optimized to new drugs useful for the treatment of Parkinson's disease, as adjuncts in levodopa based therapy, or for the treatment of schizophrenia.

Compounds advantageous in the treatment of central nervous system diseases and disorders

A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia,